G
Giuseppe Mancia
Researcher at University of Milano-Bicocca
Publications - 1465
Citations - 152794
Giuseppe Mancia is an academic researcher from University of Milano-Bicocca. The author has contributed to research in topics: Blood pressure & Ambulatory blood pressure. The author has an hindex of 145, co-authored 1369 publications receiving 139692 citations. Previous affiliations of Giuseppe Mancia include University of Milan & Instituto Politécnico Nacional.
Papers
More filters
Journal ArticleDOI
Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy.
Julie K K Vishram,Björn Dahlöf,Richard B. Devereux,Hans Ibsen,Sverre E. Kjeldsen,Lars H Lindholm,Giuseppe Mancia,Peter M. Okin,Peter M. Rothwell,Kristian Wachtell,Michael H. Olsen +10 more
TL;DR: In LIFE patients, higher in-treatment BP6–24months variability was independently of mean BP6-24months associated with later CEP and stroke, but not with MI or TOD after 24 months.
Journal ArticleDOI
Absolute and relative changes in carotid intima-media thickness and atherosclerotic plaques during long-term antihypertensive treatment: Further results of the European Lacidipine Study on Atherosclerosis (ELSA)
Alberto Zanchetti,M. Gene Bond,M. Hennig,Rong Tang,Regina Hollweck,Giuseppe Mancia,Lothar Eckes,Dino Micheli +7 more
TL;DR: The relative benefit of lacidipine over atenolol could be measured precisely by reading scans either during the study or at study-end, however, absolute treatment-related changes cannot safely be judged by readings made during a long-term study, unless a longitudinal quality control of readings is performed.
Journal ArticleDOI
The polypill in cardiovascular prevention: evidence, limitations and perspective - position paper of the European Society of Hypertension.
A. Coca,Enrico Agabiti-Rosei,Renata Cifkova,Athanasios J. Manolis,Josep Redon,Giuseppe Mancia +5 more
TL;DR: It is argued that the high prevalence of individuals with a multifactorial risk profile provides a strong rationale for a therapeutic strategy based on the combination in a single tablet of drugs against different risk factors, supporting use of the polypill in secondary cardiovascular prevention.
Journal ArticleDOI
Prognostic Value of Long-Term Blood Pressure Variability: The Evidence Is Growing
TL;DR: Evidence has been obtained that some of the daily BP peaks and the morning BP rise are independently related to organ damage and the risk of cardiovascular events, and this is also the case for markers of overall BP variability.
Journal ArticleDOI
Blood pressure variability, cardiovascular risk and antihypertensive treatment.
TL;DR: The ability of antihypertensive agents to actually reduce 24-h blood pressure variability needs to be demonstrated in future studies, using beat-to-beat blood pressure monitoring which is now possible by means of non-invasive techniques.